Alexa B. Kimball

27.9k total citations · 11 hit papers
364 papers, 17.4k citations indexed

About

Alexa B. Kimball is a scholar working on Dermatology, Immunology and Surgery. According to data from OpenAlex, Alexa B. Kimball has authored 364 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Dermatology, 130 papers in Immunology and 94 papers in Surgery. Recurrent topics in Alexa B. Kimball's work include Psoriasis: Treatment and Pathogenesis (115 papers), Hidradenitis Suppurativa and Treatments (94 papers) and Dermatology and Skin Diseases (88 papers). Alexa B. Kimball is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (115 papers), Hidradenitis Suppurativa and Treatments (94 papers) and Dermatology and Skin Diseases (88 papers). Alexa B. Kimball collaborates with scholars based in United States, Germany and Canada. Alexa B. Kimball's co-authors include Kim Papp, Kenneth B. Gordon, Shu Li, Craig L. Leonardi, Gregor B. E. Jemec, Newman Yeilding, Jack Resneck, Cynthia Guzzo, Andrew Blauvelt and Yuhua Wang and has published in prestigious journals such as The Lancet, JAMA and The Journal of Experimental Medicine.

In The Last Decade

Alexa B. Kimball

353 papers receiving 16.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

2008 1.4k citations Alexa B. Kimball, Kim Papp et al. profile →
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

2007 695 citations Stephen K. Tyring, Alexa B. Kimball et al. Journal of the American Academy of Dermatology profile →
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

2017 637 citations Andrew Blauvelt, Kim Papp et al. Journal of the American Academy of Dermatology profile →
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis

2006 565 citations Alexa B. Kimball et al. profile →
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

2017 413 citations Kristian Reich, Kim Papp et al. profile →
Hidradenitis suppurativa

2020 364 citations Gregor B. E. Jemec, Alexa B. Kimball et al. profile →
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

2012 305 citations Alexa B. Kimball, Francisco A. Kerdel et al. profile →
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

2019 224 citations Afsáneh Alavi, Alice B. Gottlieb et al. Journal of the American Academy of Dermatology profile →
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

2019 222 citations Afsáneh Alavi, Alice B. Gottlieb et al. Journal of the American Academy of Dermatology profile →
Impact of Endometriosis on Life-Course Potential: A Narrative Review

2021 123 citations Stacey A. Missmer, Frank F. Tu et al. International Journal of General Medicine profile →
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

2024 71 citations Alexa B. Kimball, Gregor B. E. Jemec et al. profile →

Peers

Countries citing papers authored by Alexa B. Kimball

Since Specialization

Citations

This map shows the geographic impact of Alexa B. Kimball's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexa B. Kimball with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexa B. Kimball more than expected).

Fields of papers citing papers by Alexa B. Kimball

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexa B. Kimball. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexa B. Kimball. The network helps show where Alexa B. Kimball may publish in the future.

Co-authorship network of co-authors of Alexa B. Kimball

This figure shows the co-authorship network connecting the top 25 collaborators of Alexa B. Kimball. A scholar is included among the top collaborators of Alexa B. Kimball based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexa B. Kimball. Alexa B. Kimball is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa 2025 ·British Journal of Dermatology ·John R Ingram, Magdalena B. Wozniak, Anna Passera, Lorenz Uhlmann, (unknown), Falk G. Bechara, Randall H. Bender, Lori McLeod, Susan Martin, Santiago G. Moreno, Jessica Marvel, Shoba Ravichandran, Alexa B. Kimball	0
2	Cumulative life course impairment: Evidence for hidradenitis suppurativa 2025 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), (unknown), (unknown), (unknown), Alexa B. Kimball	1
3	092 Efficacy and safety of the oral Bruton’s tyrosine kinase inhibitor, remibrutinib, in patients with moderate to severe hidradenitis suppurativa in a randomized, phase 2, double-blind, placebo-controlled platform study 2024 ·Journal of Investigative Dermatology ·Jóhann E. Guðjónsson, Alexa B. Kimball, Errol P. Prens, (unknown), Byoung Wook Bang, (unknown), Christian Loesche	4
4	Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials 2023 ·SKIN The Journal of Cutaneous Medicine ·Alexa B. Kimball, Afsáneh Alavi, Gregor B. E. Jemec, Alice B. Gottlieb, Xiaoling Wei, Magdalena B. Wozniak, Lorenz Uhlmann, (unknown), Deborah Keefe, Ruvie Martin, Li Chen, Elisa Muscianisi	5
5	Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study 2023 ·SKIN The Journal of Cutaneous Medicine ·Afsáneh Alavi, Errol P. Prens, Alexa B. Kimball, James G. Krueger, (unknown), Hui Wang, (unknown), (unknown), Christos C. Zouboulis	6
6	Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial 2023 ·British Journal of Dermatology ·Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball	16
7	Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape 2023 ·British Journal of Dermatology ·James G. Krueger, John W. Frew, Gregor B. E. Jemec, Alexa B. Kimball, Brian Kirby, Falk G. Bechara, Kristina Navrazhina, Errol P. Prens, Kristian Reich, (unknown), Kerstin Wolk	33
8	Early onset of senescence and imbalanced epidermal homeostasis across the decades in photoexposed human skin: Fingerprints of inflammaging 2022 ·Experimental Dermatology ·Bradley B. Jarrold, (unknown), Chin Yee Ho, (unknown), TuKiet T. Lam, Xiaojing Yang, (unknown), Wei Guo, Yap Ching Chew, Yvonne M. DeAngelis, Lydia Costello, (unknown), Stefan Przyborski, Sophie Bellanger, Oliver Dreesen, Alexa B. Kimball, John E. Oblong	18
9	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1) 2022 ·British Journal of Dermatology ·Andrew Blauvelt, Alexa B. Kimball, Matthias Augustin, Yukari Okubo, Michael M. Witte, (unknown), (unknown), Vipin Arora, Olawale Osuntokun, Bruce Strober	29
10	Impact of Endometriosis on Life-Course Potential: A Narrative Review breakdown → 2021 ·International Journal of General Medicine ·Stacey A. Missmer, Frank F. Tu, Sanjay K. Agarwal, Charles Chapron, Ahmed M. Soliman, Stephanie E. Chiuve, Samantha Eichner, Idhaliz Flores, Andrew W. Horne, Alexa B. Kimball, Marc R. Laufer, Nicholas Leyland, Sukhbir S. Singh, Hugh S. Taylor, Sawsan As‐Sanie	123
11	Aging-Associated Changes in the Adult Human Skin Microbiome and the Host Factors that Affect Skin Microbiome Composition 2021 ·Journal of Investigative Dermatology ·Brian W. Howard, Charles C. Bascom, Ping Hu, Robert L. Binder, Gina M. Fadayel, (unknown), Bradley B. Jarrold, Rosemarie Osborne, Heather L. Rocchetta, (unknown), Jay P. Tiesman, (unknown), (unknown), Kenneth R. Wehmeyer, Alexa B. Kimball, Robert J. Isfort	66
12	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact 2020 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Joelle M. van der Walt, Andrew Blauvelt, Caitriona Ryan, P.C.M. van de Kerkhof, Alexa B. Kimball	17
13	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice 2020 ·American Journal of Clinical Dermatology ·Errol P. Prens, Aída Lugo‐Somolinos, Amy S. Paller, Francisco A. Kerdel, Yinghui Duan, Henrique D. Teixeira, (unknown), Alexa B. Kimball	16
14	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies 2019 ·British Journal of Dermatology ·Alexa B. Kimball, Kim Papp, Kristian Reich, Melinda Gooderham, Q. Li, N. Cichanowitz, Carmen La Rosa, Andrew Blauvelt	23
15	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab 2019 ·British Journal of Dermatology ·Alexa B. Kimball, Thomas Kerbusch, (unknown), (unknown), (unknown), Andrew Blauvelt, Kim Papp, Kristian Reich, Diana Montgomery	21
16	Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa 2018 ·Journal of the European Academy of Dermatology and Venereology ·Alexa B. Kimball, Arijit Ganguli, Alan B. Fleischer	14
17	Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis. 2018 ·PubMed ·Alexa B. Kimball, Murali Sundaram, Martin Cloutier, Marjolaine Gauthier‐Loiselle, Patrick Gagnon‐Sanschagrin, Annie Guérin, Arijit Ganguli	4
18	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials 2018 ·British Journal of Dermatology ·Andrew Blauvelt, Kristian Reich, Kim Papp, Alexa B. Kimball, Melinda Gooderham, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Q. Li, N. Cichanowitz, (unknown), Carmen La Rosa	60
19	An assessment of the cost-utility of therapy for psoriasis 2006 ·Therapeutics and Clinical Risk Management ·Stefan Weiß, Wingfield Rehmus, Alexa B. Kimball	9
20	5% dapsone topical gel: Safety and efficacy with long-term (1 year) treatment for acne vulgaris 2005 ·Journal of the American Academy of Dermatology ·Philip T. Liu, (unknown), Robert L. Modlin, (unknown), (unknown), Alexa B. Kimball	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact